PET imaging in patients with brain metastasis-report of the RANO/PET group.
- Galldiks N Department of Neurology, University Hospital Cologne, Cologne, Germany.
- Langen KJ Institute of Neuroscience and Medicine 3, 4, Research Center Juelich, Juelich, Germany.
- Albert NL Department of Nuclear Medicine, Ludwig Maximilians-University of Munich, Munich, Germany.
- Chamberlain M Departments of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA.
- Soffietti R Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy.
- Kim MM Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
- Law I Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Denmark.
- Le Rhun E Department of Neurosurgery, University Hospital Lille, Lille, France.
- Chang S Department of Neurosurgery, University of California, San Francisco, California, USA.
- Schwarting J Department of Neurosurgery, Ludwig Maximilians-University of Munich, Munich, Germany.
- Combs SE Department of Radiation Oncology, Technical University Munich, Munich, Germany.
- Preusser M Department of Medicine I and Comprehensive Cancer Centre CNS Tumours Unit, Medical University of Vienna, Vienna, Austria.
- Forsyth P Moffitt Cancer Center, University of South Florida, Tampa, Florida, USA.
- Pope W Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California , USA.
- Weller M Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
- Tonn JC Department of Neurosurgery, Ludwig Maximilians-University of Munich, Munich, Germany.
- 2019-01-08
Published in:
- Neuro-oncology. - 2019
FDG PET
FET
amino acid PET
brain metastases
pseudoprogression
Animals
Brain Neoplasms
Humans
Molecular Imaging
Positron-Emission Tomography
Radiopharmaceuticals
English
Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, including radiosurgery or fractionated external beam radiotherapy, and surgical resection. The use of systemic treatment for intracranial disease control also is improving. BM diagnosis, treatment planning, and follow-up is most often based on contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging modalities including standard MRI have limitations in accurately characterizing posttherapeutic reactive changes and treatment response. Molecular imaging techniques such as positron emission tomography (PET) characterize specific metabolic and cellular features of metastases, potentially providing clinically relevant information supplementing anatomic MRI. Here, the Response Assessment in Neuro-Oncology working group provides recommendations for the use of PET imaging in the clinical management of patients with BM based on evidence from studies validated by histology and/or clinical outcome.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1093/neuonc/noz003
- PMID 30615138
- Persistent URL
- https://folia.unifr.ch/global/documents/18490
Statistics
Document views: 7
File downloads:
- fulltext.pdf: 0